pillbase.ru

OCREVUS

Active substance: ocrelizumab

INJECTION · OCRELIZUMAB 300 mg/10mL

United StatesActive

Marketing holder: Genentech, Inc.

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
RU 3
  • Окревус®
    концентрат для приготовления раствора для инфузий, 30 мг/мл, 10 мл (original in Russian, GRLS)
    ЛП-004503
    Ф. Хоффманн-Ля Рош Лтд.
  • Окревус®
    концентрат для приготовления раствора для инфузий, 300 мг, 10 мл (original in Russian, GRLS)
    ЛП-№(003473)-(РГ-RU)
    Ф.Хоффманн-Ля Рош Лтд
  • Окревус®
    раствор для подкожного введения, 920 мг, 23 мл (original in Russian, GRLS)
    ЛП-№(016128)-(РГ-RU)
    Ф.Хоффманн-Ля Рош Лтд
EU 1
  • Ocrevus
    ocrelizumab
    EMEA/H/C/004043
    Roche Registration GmbH
Import and control

Control by country

  • Russiaprescription only

    Source: GRLS (Russian state register) · record 01a120c3-2fe9-7ae6-85e4-405dc5672986,01a120c3-54c3-7a50-8af2-77bb45290e15,01a120c3-f8c5-7032-920a-c4d592f8b263;count=3 · valid from 2026-10-09 · verified 2026-10-09

  • United Statesprescription only

    Source: openFDA NDC · record 01a12093-93bf-762b-9927-493f2dcd6314;count=1 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
50242-150
Registration status
Active
Dispensing
Prescription only
Route
INTRAVENOUS
Sources
  • product · openFDA NDC · 50242-150 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 50242-150 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 50242-150 · Verified 2026-10-09 · open in source